{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.59","value":"12.2"},{"groupId":"OG001","spread":"8.03","value":"15.5"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.98","value":"30.5"},{"groupId":"OG001","spread":"56.78","value":"68"}]}],"title":"Day 43"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"The weighted mean platelet count is defined as the area under the platelet-time curve divided by the duration of the treatment (12 weeks). Based on the Analysis of Covariance (ANCOVA) model, the weighted mean platelet count is the sum of the Baseline count plus the age cohort plus the treatment. Baseline was defined as the platelet count taken on Day 1 or within 48 hours prior to the first dose of treatment.","dispersionType":"Standard Deviation","groups":[{"description":"Par aged between 1 and 17 years (Cohort 1 age group: 12 to 17 years, Cohort 2: 6 to 11 years and Cohort 3:1 to 5 years) received eltrombopag matching placebo for 7 weeks.","id":"OG000","title":"Part 2 (Randomized Period) -Placebo"},{"description":"Par aged between 1 and 17 years (Cohort 1 age group: 12 to 17 years, Cohort 2: 6 to 11 years and Cohort 3:1 to 5 years) received eltrombopag for 7 weeks. The starting dose for Cohort 1 was 37.5 mg QD. For Cohort 2, starting dose was based on the body weight. Par with a body weight of \\<27 kg received 25 mg QD, and par with a body weight of \\>=27 kg received 50 mg QD. Par of East Asian ancestry with a body weight of \\<27 kg received 12.5 mg QD, and with a body weight of \\>=27 kg received 25 mg QD. For Cohort 3, the starting dose was 1.5 mg/kg QD and 0.8 mg/kg/day for par of East Asian ancestry. The maximum dose allowed was 2mg/kg and could not exceed 75 mg daily. For all par, individual dose titration was allowed based upon platelet response.","id":"OG001","title":"Part 2 (Randomized Period) - Eltrombopag"}],"paramType":"MEAN","populationDescription":"ITT Population. Only participants during Part 2 with a value at baseline and post-baseline were considered for analysis","reportingStatus":"POSTED","timeFrame":"Baseline and Day 43 of Part 2","title":"Weighted Mean Platelet Count","type":"SECONDARY","unitOfMeasure":"Gi/L"}